Press Releases

November 5, 2018
SOUTH SAN FRANCISCO, Calif. , Nov. 05, 2018 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to present at two investor
October 10, 2018
SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--Allogene Therapeutics, Inc., a clinical-stage biotechnology company pioneering the development of allogeneic CAR T(AlloCAR T™) therapies for cancer, today announced the pricing of its initial public offering of 18,000,000 shares of its common stock at
Displaying 1 - 10 of 20
Print Page
E-mail Alerts
RSS
Investor Contacts